The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...
The primary combined endpoint occurred in 26.8% of patients in the rivaroxaban group vs 46.9% of those in the placebo group, with 1-year survival probabilities of 78.7% vs 54.4% and 2-year survival ...
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy reduced the risks for major cardiovascular events (MACE) and major bleeding across all adult ...
Drug manufacturer Bayer AG faces lawsuits in the United States for its blood-thinning drug Xarelto along with Johnson & Johnson, which markets Xarelto in the United States, according to news reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback